Li Xiaoqian, Li Xiaolu, Jinfeng Zhang, Yu Tao, Zhang Bei, Yang Yanyan
Department of Immunology, School of Basic Medicine, Qingdao University, No. 308 Ningxia Road, Qingdao, 266021, 266071, Shandong, People's Republic of China.
Institute for Translational Medicine, The Affiliated Hospital of Qingdao University, No. 38 Dengzhou Road, Qingdao, 266021, Shandong, People's Republic of China.
Inflamm Res. 2025 Jan 8;74(1):13. doi: 10.1007/s00011-024-01989-z.
Acute pancreatitis (AP) represents a severe inflammatory condition of the exocrine pancreas, precipitating systemic organ dysfunction and potential failure. The global prevalence of acute pancreatitis is on an ascending trajectory. The condition carries a significant mortality rate during acute episodes. This underscores the imperative to elucidate the etiopathogenic pathways of acute pancreatitis, enhance comprehension of the disease's intricacies, and identify precise molecular targets coupled with efficacious therapeutic interventions. The pathobiology of acute pancreatitis encompasses not only the ectopic activation of trypsinogen but also extends to disturbances in calcium homeostasis, mitochondrial impairment, autophagic disruption, and endoplasmic reticulum stress responses. Notably, the realm of epigenetic regulation has garnered extensive attention and rigorous investigation in acute pancreatitis research over recent years. One of these modifications, lysine acetylation, is a reversible post-translational modification of proteins that affects enzyme activity, DNA binding, and protein stability by changing the charge on lysine residues and altering protein structure. Numerous studies have revealed the importance of acetylation modification in acute pancreatitis, and that it is a favorable target for the design of new drugs for this disease. This review centers on lysine acetylation, examining the strides made in acute pancreatitis research with a focus on the contributory role of acetylomic alterations in the pathophysiological landscape of acute pancreatitis, thereby aiming to delineate novel therapeutic targets and advance the development of more efficacious treatment modalities.
急性胰腺炎(AP)是一种外分泌性胰腺的严重炎症性疾病,可引发全身器官功能障碍和潜在衰竭。急性胰腺炎的全球患病率呈上升趋势。该疾病在急性发作期间具有显著的死亡率。这凸显了阐明急性胰腺炎的病因发病途径、加深对该疾病复杂性的理解以及确定精确分子靶点和有效治疗干预措施的紧迫性。急性胰腺炎的病理生物学不仅包括胰蛋白酶原的异位激活,还延伸至钙稳态紊乱、线粒体损伤、自噬破坏和内质网应激反应。值得注意的是,近年来表观遗传调控领域在急性胰腺炎研究中受到了广泛关注和深入研究。其中一种修饰,赖氨酸乙酰化,是蛋白质的一种可逆翻译后修饰,它通过改变赖氨酸残基上的电荷和改变蛋白质结构来影响酶活性、DNA结合和蛋白质稳定性。众多研究已经揭示了乙酰化修饰在急性胰腺炎中的重要性,并且它是该疾病新药设计的一个有利靶点。本综述围绕赖氨酸乙酰化展开,审视急性胰腺炎研究中取得的进展,重点关注乙酰化组改变在急性胰腺炎病理生理格局中的作用,从而旨在描绘新的治疗靶点并推动更有效治疗方式的发展。